Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application
Immunological Reviews · 2024-01 · 321 (1) · 335-349
DOI: 10.1111/imr.13263 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 18.08.2023. Verfasst von François Ghiringhelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunogenic Cell Death. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Even though the discovery of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, a high proportion of patients do not respond. Moreover, some types of cancers are refractory to these treatments. Thus, the need to find predictive biomarkers of efficacy and to evaluate the association with other treatments, such as chemotherapy or radiotherapy, appears to be essential. Because ICIs reactivate or maintain an active status of T cells, one possibility is to combine these treatments with therapies that engage an immune response against tumor cells. Thus, by inducing immunogenic cell death (ICD) of cancer cells, some conventional anticancer treatments induce such immune response and may have an interest to be combined with ICIs. In this review, we explore preclinical studies and clinical trials that evaluate the combination of ICIs with ICD inducers. More than inducing ICD, some of these treatments appear to modulate the tumor microenvironment and more particularly to inhibit immunosuppression, thus improving treatment efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.
- Equipe TIRECs, Labellisée Ligue Contre le Cancer, Centre de Recherche INSERM LNC-UMR1231, Dijon, France.
- University of Bourgogne Franche-Comté, Dijon, France.
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- Genetic and Immunology Medical Institute, Dijon, France.
ORCID-Profile: Cédric Rébé
Zitieren
APA
Ghiringhelli, F., & Rébé, C. (2024). Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application. Immunological Reviews, 321(1), 335-349. https://doi.org/10.1111/imr.13263
Vancouver
Ghiringhelli F, Rébé C. Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application. Immunological Reviews. 2024;321(1):335-349. doi:10.1111/imr.13263
BibTeX
@article{Ghiringhelli2024,
author = {Ghiringhelli, François and Rébé, Cédric},
title = {Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application},
journal = {Immunological Reviews},
year = {2024},
volume = {321},
number = {1},
pages = {335--349},
doi = {10.1111/imr.13263}
}
EUVIMED